328 results about "Psoriasis" patented technology

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.

The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

The present invention relates to a traditional Chinese medicine composition for treating psoriasis, and its preparation method and use. The traditional Chinese medicine composition is prepared from the following raw materials: Portulaca oleracea, Sophora flavescens, Dictamni bark, Honeysuckle, Kochia scoparia, Phellodendron amurense, Platycladus orientalis leaves, Paeonia lactiflora, and Lithospermum officinale. The traditional Chinese medicine composition of the present invention has a scientific and reasonable formulation, synergistic efficacy, a small number of ingredients, and controlled quality. The combination of monarch, minister, adjuvant, and envoy in the present invention's formulation is scientific and reasonable. The combination of anti-inflammatory and immunomodulatory heat-clearing, blood-cooling, and antipruritic drugs can effectively eliminate the cause of the disease and enhance the antipruritic effect, exerting anti-inflammatory, antiproliferative, and local vasoconstrictive effects, with the advantages of increased efficacy and reduced toxicity, and can reduce the risk of recurrence. This promotes epithelial tissue repair, maintains the dynamic balance of skin keratinization, effectively prevents the recurrence of psoriasis, and reduces the suffering of patients.

A perilla leaf-derived nanovesicle and the use thereof in the preparation of a product with anti-inflammatory efficacy. The nanovesicle can be phagocytosed and internalized by HaCaT cells, reduce the levels of ROS and inflammatory factors in HaCaT cells, and exert an anti-inflammatory effect. Meanwhile, the nanovesicle has excellent transdermal properties, and thus can effectively alleviate and treat psoriatic dermatitis symptoms in mice. The nanovesicle can also be added as an active ingredient to different matrices to form compositions.

Described herein are methods for treating an autoimmune or inflammatory disease in a patient, comprising administering a composition comprising: a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2353-367, PDC-E272-86, and PDC-E2422-436 for DRB3*0202; PDC-E2353-367, PDC-E280-94, and PDC-E2535-549 for DRB5*0101; PDC-E2629-648, PDC-E2122-135, and PDC-E2249-263 for DRB4*0101; and PDC-E2249-263 for DRB1*0801; and b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers; wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.

The invention discloses application of METTL1 as a target spot in preparation of a medicine for treating erythema squamous skin diseases, relates to the field of biological medicines, provides a new scheme for treatment of erythema squamous skin diseases, especially psoriasis and atopic dermatitis, relieves inflammatory response of psoriasis or atopic dermatitis by inhibiting expression of METTL1, and provides a new application of METTL1 as a target spot in preparation of medicines for treating erythema squamous skin diseases, especially psoriasis and atopic dermatitis. And erythema, scales and skin thickness are reduced.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The invention discloses application of pedunculoside in preparation of a medicine for treating psoriasis, and relates to the technical field of medicines. The invention provides a natural candidate drug which is clear in structure and has both effectiveness and safety for clinical treatment of psoriasis.

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention discloses a pharmaceutical composition for treating psoriasis and application thereof. The active ingredient of the composition is a combination of Mongolian medicine seven-ingredient powder soup and a horse bone extracting solution, wherein the Mongolian medicine seven-ingredient powder is prepared from radix sophorae flavescentis, elecampane, fructus chebulae, szechwan chinaberry fruit, fructus gardeniae, herba violae and rhizoma picrorhizae according to a specific proportion. The preparation method of the composition mainly comprises the following steps: respectively preparing Mongolian medicine seven-component powder soup and horse bone extracting solution, and then mixing and decocting the Mongolian medicine seven-component powder soup and the horse bone extracting solution. Through the synergistic interaction of the Mongolian medicine seven-ingredient powder decoction and the horse bone extracting solution, the composition shows a treatment effect superior to that of independent use of each component in an animal model, and can remarkably relieve psoriasis-like skin lesion and down-regulate the expression of related inflammatory factors. The invention provides an application of the composition in preparation of a medicine for treating psoriasis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

The invention relates to application of oxymatrine in preparation of a medicine for treating a patient suffering from erythroderma psoriasis and the like.

Disclosed is use of danshensu or a pharmaceutically acceptable salt thereof as a PI3K / AKT / mTOR signaling pathway inhibitor in the preparation of a drug for treating psoriasis. Pharmacological experiments reveal that danshensu can inhibit the phosphorylation of the PI3K / AKT / mTOR signaling pathway to significantly ameliorate psoriasis-like skin lesions on mice and reduce the excessive proliferation and abnormal differentiation of epidermal cells and the expression of CCL20mRNA in skin lesions. In vitro experiments show that danshensu can inhibit TNF-α-induced HaCaT cell proliferation and inhibit the generation and secretion of the pro-inflammatory factors IL-6, IL-8, and IFN-γ and the chemokine CCL20. The use of danshensu to prepare a drug for treating psoriasis opens up a new field of application for danshensu.

The present disclosure relates to an orthogonal system comprising a first bi-specific polypeptide that comprises D-streptavidin or a variant thereof covalently linked to an antibody or antibody fragment and a second bi-specific polypeptide that comprises L-biotin covalently linked to a therapeutic or diagnostic agent. The disclosed systems can be useful in, for example, treating a disease or a condition (e.g., cancer, non-Hodgkin lymphoma, multiple sclerosis, Crohn's disease, rheumatoid arthritis, asthma, macular degeneration, psoriasis, Hodgkin lymphoma, paroxysmal nocturnal hemoglobinuria, X-linked hypophosphatemia). Also described are peptides and polypeptides useful in preparing the disclosed bi-specific polypeptides and methods of making same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention concerns methods and pharmaceutical compositions for use in the treatment of psoriasis comprising as an active ingredient piclidenoson (IB-MECA) in an amount suitable for a daily dose administration of about 6 milligrams (mg).

The invention provides a preparation method of traditional Chinese medicine hydrogel for treating psoriasis, the hydrogel preparation is prepared from the following raw material medicines in parts by weight: 20-40 parts of PVA, 60-80 parts of borax, 20-40 parts of glycyrrhizic acid, 8-12 parts of paeoniflorin and 2-3 parts of glycerin, the hydrogel has the advantages of injectability, self-healing, stretchability and the like, can meet the requirements of skin dressing, can be tightly attached to the skin, and has a good application prospect. The separation is easy. Animal experiments prove that after being loaded with paeoniflorin, the gel has the curative effect of treating mild and moderate psoriasis, the treatment effect is remarkable, and the gel has a wide market application prospect.

The present invention relates to a peptide inhibitor of an interleukin-23 receptor and a use thereof. In particular, the present invention relates to peptide inhibitors of the interleukin-23 receptor, stereoisomers or pharmaceutically acceptable salts or solvates thereof, pharmaceutical compositions thereof, and uses of the peptide inhibitors in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

This invention discloses a class of PDE4 degrading agents or their pharmaceutical salts for treating psoriasis, with a general structural formula selected from one of the following structures: The PDE4 degrading agents for treating psoriasis provided by this invention offer a new strategy for in-depth research and development of novel structural types of anti-psoriasis drugs. The compounds of this invention exhibit excellent in vitro degradation activity against PDE4 protein.

The present invention relates to a flexible skin patch equipped with an ultra-thin LED assembly that emits light in a specific wavelength range and an invention for manufacturing the same, and is related to an invention capable of providing a flexible skin patch that has the excellent effect of promoting vitamin D production in a localized area of the skin, and has the effect of alleviating or treating local skin psoriasis, fungi, fungal tumors and eczema, and has excellent antiviral effect, and is easy to attach and detach.

Provided are a novel peptide inhibitor of the interleukin-23 receptor, a stereoisomer or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same, and the use of the peptide inhibitor in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to a peptide inhibitor of interleukin-23 receptor, and a use thereof. In particular, it relates to a peptide inhibitor of interleukin-23 receptor, a stereoisomer, pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and a use of the peptide inhibitor in treating or preventing diseases or conditions comprising inflammatory bowel disease, Crohn's disease, and psoriasis.

1. Name of the product in this design: Ultraviolet Phototherapy Device (308 nm). 2. Intended use of this design: Treatment of psoriasis and vitiligo. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

Sesterterpenoid compounds and an extract L01 of Leucosceptrum canum, and use thereof in treatment of psoriasis are provided, belonging to the technical field of natural medicinal chemistry. The sesterterpenoid compound of the Leucosceptrum canum has a structure shown in any one of Formulas 9 to 12, which shows a highly rare backbone type, exhibits anti-inflammatory and immunosuppressive activities, and can be used in preparation of an anti-inflammatory drug and an immunosuppressive drug. A Leucosceptrum canum extract L01 having compounds 1 to 12 as characteristic ingredients, and use thereof in preparation of an anti-inflammatory drug and an immunosuppressive drug are further provided.

The present invention relates to the technical field of traditional Chinese medicine, and provides a Chinese medicine composition for treating skin lesions and scars, and a preparation method and application thereof, which is mainly used to treat skin lesions and scars caused by carbuncle and ulcer. The Chinese medicine composition of the present invention comprises the following raw materials: Vaccaria segetalis, Astragalus membranaceus, Bletilla striata, Morus alba bark, Angelica dahurica, White Ampelopsis Root, Dictamni Cortex, Rhizoma Cyperi, Rhizoma Bletillae, Bletilla striata Rhizoma, Bletilla striata Rhizoma, Bletilla striata Rhizoma, Bletilla striata Rhizoma, Bark of Bombyx batryticatus, Magnolia officinalis, Pueraria root, Eucommia bark, Dipsacus asper, Smilax glabra, Honeysuckle vine, Chuanxiong, Angelica sinensis, Ephedra sinica, and Cinnamomum cassia. The Chinese medicine composition of the present invention has the effects of dispelling wind and relieving itching, relieving swelling and relieving pain, promoting pus and detoxifying, and reducing color and eliminating scars. It is mainly used to treat skin lesions and scars caused by carbuncle and ulcer, and is significantly effective for treating skin ulcers, swellings, and furuncles. It also treats pruritus caused by deep infected wounds and psoriasis lesions, and reduces the use of antibiotics.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.